Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jul 15;17(14):3872-6.
doi: 10.1016/j.bmcl.2007.05.004. Epub 2007 May 6.

Antiproliferative and apoptosis inducing properties of pyrano[3,2-c]pyridones accessible by a one-step multicomponent synthesis

Affiliations

Antiproliferative and apoptosis inducing properties of pyrano[3,2-c]pyridones accessible by a one-step multicomponent synthesis

Igor V Magedov et al. Bioorg Med Chem Lett. .

Abstract

4-Arylpyrano-[3,2-c]-pyridones have been prepared by a one-step cyclocondensation of 4-hydroxy-1,6-dimethylpyridin-2(1H)-one with various substituted benzaldehydes and malononitrile. These heterocycles exhibit micromolar and submicromolar antiproliferative activity in HeLa and induce apoptosis in Jurkat cell lines. Structure-activity studies performed on a small library of these compounds show a pronounced cytotoxicity enhancing effect of the bromo substituent at the meta position of the C4 aromatic moiety.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of biologically active 2-pyridone-containing compounds.
Figure 2
Figure 2
Structures of the scaffold A, pyranopyridone library B and chromene library C.
Figure 3
Figure 3
Three-component synthesis of pyrano-[3,2-c]-pyridones.
Figure 4
Figure 4
Induction of apoptosis in Jurkat cells treated for 36 h with DMSO control, colchicine (5 μM) and selected pyridone library analogues (5 μM) in flow cytometric annexin-V/propidium iodide assay. Error bars represent data from two experiments.
Figure 5
Figure 5
Jurkat cells after 48 h treatment with DMSO control (A), inactive compound 11 (B) and potent analogue 3 (C).

References

    1. See Gorobets NYu, Yousefi BH, Belaj F, Kappe CO. Tetrahedron. 2004;60:8633. and references cited therein.

    1. Pettit GR, Du J, Pettit RK, Richert LA, Hogan F, Mukku JVRV, Hoard MS. J Nat Prod. 2006;69:804. - PubMed
    1. Saag MS, Emini EA, Laskin OL, Douglas J, Lapidus WI, Schleif WA, Whitley RJ, Hildebrand C, Byrnes VW, Kappes JC, Anderson KW, Massari FE, Shaw GM. N Engl J Med. 1993;329:1065. - PubMed
    1. Hasegawa GR. Clin Pharmacy. 1986;5:201. - PubMed
    1. Choudhari BP, Mulwad VV. Indian J Chem Sect B-Org Chem Incl Med Chem. 2003;42:2080.
    2. Balasubramanian C, Sekar M, Mohan PS. Indian J Chem Sect B-Org Chem Incl Med Chem. 1996;35:1225.

Publication types